Background: Despite the availability of potent antiretroviral regimens (combination
antiretroviral therapy [cART]), HIV-associated neurocognitive disorders (HAND) are …

With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-
associated dementia, as it was termed later, largely disappeared in clinical practice …

Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4+ T cells and cells of the
monocyte–macrophage lineage, resulting in immunodeficiency in an infected patient. Along …

Many practical clinical questions regarding the management of human immunodeficiency
virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to …

ABSTRACT HIV continues to be a global health crisis with more than 34 million people
infected worldwide (UNAIDS: Report on the Global AIDS Epidemic 2010, Geneva, World …

Objective: Differences in antiretroviral distribution into the central nervous system (CNS) may
impact neurocognitive status. We assessed the relationship between estimates of …

The overall purpose of these guidelines is to provide guidance on best clinical practice for
antiretroviral therapy (ART) and management of adults living with human immunodeficiency …

Whilst effective antiretroviral therapy is protective against the more severe forms of HIV-
associated brain disease, there remains a large burden of clinically symptomatic cognitive …

Background Prevalence of neurocognitive impairment in HIV-1 infected patients is reported
to be high. Whether this is a result of active HIV-related neurodegeneration is unclear. We …

HIV-associated neurocognitive disorder is known to occur in the context of successful
combination antiretroviral therapy (cART; plasma HIV RNA< 50 copies/ml). Here, we newly …